These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 23373812)

  • 1. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
    Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
    J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dysfunction of hepatic transcriptional factors in mice with Huntington's Disease.
    Chiang MC; Chern Y; Juo CG
    Biochim Biophys Acta; 2011 Sep; 1812(9):1111-20. PubMed ID: 21651979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transducer of regulated CREB-binding proteins (TORCs) transcription and function is impaired in Huntington's disease.
    Chaturvedi RK; Hennessey T; Johri A; Tiwari SK; Mishra D; Agarwal S; Kim YS; Beal MF
    Hum Mol Genet; 2012 Aug; 21(15):3474-88. PubMed ID: 22589249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma.
    Chiang MC; Chen CM; Lee MR; Chen HW; Chen HM; Wu YS; Hung CH; Kang JJ; Chang CP; Chang C; Wu YR; Tsai YS; Chern Y
    Hum Mol Genet; 2010 Oct; 19(20):4043-58. PubMed ID: 20668093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PPARgamma rescue of the mitochondrial dysfunction in Huntington's disease.
    Chiang MC; Chern Y; Huang RN
    Neurobiol Dis; 2012 Jan; 45(1):322-8. PubMed ID: 21907283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model.
    Lu Z; Marks E; Chen J; Moline J; Barrows L; Raisbeck M; Volitakis I; Cherny RA; Chopra V; Bush AI; Hersch S; Fox JH
    Neurobiol Dis; 2014 Nov; 71():34-42. PubMed ID: 25014023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.
    Chaturvedi RK; Calingasan NY; Yang L; Hennessey T; Johri A; Beal MF
    Hum Mol Genet; 2010 Aug; 19(16):3190-205. PubMed ID: 20529956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease.
    Hathorn T; Snyder-Keller A; Messer A
    Neurobiol Dis; 2011 Jan; 41(1):43-50. PubMed ID: 20736066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPAR-δ is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically.
    Dickey AS; Pineda VV; Tsunemi T; Liu PP; Miranda HC; Gilmore-Hall SK; Lomas N; Sampat KR; Buttgereit A; Torres MJ; Flores AL; Arreola M; Arbez N; Akimov SS; Gaasterland T; Lazarowski ER; Ross CA; Yeo GW; Sopher BL; Magnuson GK; Pinkerton AB; Masliah E; La Spada AR
    Nat Med; 2016 Jan; 22(1):37-45. PubMed ID: 26642438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease.
    Quintanilla RA; Jin YN; Fuenzalida K; Bronfman M; Johnson GVW
    J Biol Chem; 2008 Sep; 283(37):25628-25637. PubMed ID: 18640979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosiglitazone activation of PPARγ-dependent signaling is neuroprotective in mutant huntingtin expressing cells.
    Chiang MC; Cheng YC; Nicol CJ; Lin KH; Yen CH; Chen SJ; Huang RN
    Exp Cell Res; 2015 Nov; 338(2):183-93. PubMed ID: 26362846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration.
    Cui L; Jeong H; Borovecki F; Parkhurst CN; Tanese N; Krainc D
    Cell; 2006 Oct; 127(1):59-69. PubMed ID: 17018277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease.
    Johri A; Calingasan NY; Hennessey TM; Sharma A; Yang L; Wille E; Chandra A; Beal MF
    Hum Mol Genet; 2012 Mar; 21(5):1124-37. PubMed ID: 22095692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function.
    Tsunemi T; Ashe TD; Morrison BE; Soriano KR; Au J; Roque RA; Lazarowski ER; Damian VA; Masliah E; La Spada AR
    Sci Transl Med; 2012 Jul; 4(142):142ra97. PubMed ID: 22786682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease.
    Jiang M; Peng Q; Liu X; Jin J; Hou Z; Zhang J; Mori S; Ross CA; Ye K; Duan W
    Hum Mol Genet; 2013 Jun; 22(12):2462-70. PubMed ID: 23446639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter.
    Martin E; Betuing S; Pagès C; Cambon K; Auregan G; Deglon N; Roze E; Caboche J
    Hum Mol Genet; 2011 Jun; 20(12):2422-34. PubMed ID: 21493629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease.
    Gardian G; Browne SE; Choi DK; Klivenyi P; Gregorio J; Kubilus JK; Ryu H; Langley B; Ratan RR; Ferrante RJ; Beal MF
    J Biol Chem; 2005 Jan; 280(1):556-63. PubMed ID: 15494404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models.
    Sontag EM; Lotz GP; Agrawal N; Tran A; Aron R; Yang G; Necula M; Lau A; Finkbeiner S; Glabe C; Marsh JL; Muchowski PJ; Thompson LM
    J Neurosci; 2012 Aug; 32(32):11109-19. PubMed ID: 22875942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons.
    Thomas EA; Coppola G; Tang B; Kuhn A; Kim S; Geschwind DH; Brown TB; Luthi-Carter R; Ehrlich ME
    Hum Mol Genet; 2011 Mar; 20(6):1049-60. PubMed ID: 21177255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice.
    Bradford J; Shin JY; Roberts M; Wang CE; Sheng G; Li S; Li XJ
    J Biol Chem; 2010 Apr; 285(14):10653-61. PubMed ID: 20145253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.